These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23905896)

  • 1. CYFRA21-1 as a serum tumor marker for follow-up patients with squamous cell lung carcinoma and oropharynx squamous cell carcinoma.
    Liu L; Liu B; Zhu LL; Li Y
    Biomark Med; 2013 Aug; 7(4):591-9. PubMed ID: 23905896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
    Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
    Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
    Li R; Li R; Wang Y
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients].
    Hang ZQ; Zheng MF; Huang JH
    Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):847-9. PubMed ID: 22335951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
    Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
    Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Usefulness of CYFRA21-1 as a tumor marker of non-small-cell lung cancer].
    Tan Y; Zhang P; Zheng C
    Zhonghua Zhong Liu Za Zhi; 1999 Jul; 21(4):287-9. PubMed ID: 11776818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyfra 21-1 as a tumor marker for follow-up of patients with squamous cell carcinoma of the oropharynx.
    Alkotyfan K; Wiegand S; Müller HH; Windfuhr JP; Werner JA; Sesterhenn AM
    Anticancer Res; 2010 Jun; 30(6):2291-6. PubMed ID: 20651382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Detection of serum CK19-2G2 and Cyfra21-1 protein and comparison of their diagnostic value for lung cancer].
    Gao J; Wang H; Qi J
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):930-2. PubMed ID: 19173996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
    Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal cutoff points of CYFRA21-1 for survival prediction in non-small cell lung cancer patients based on running statistical analysis.
    Takahashi H; Kurishima K; Ishikawa H; Kagohashi K; Kawaguchi M; Satoh H
    Anticancer Res; 2010 Sep; 30(9):3833-7. PubMed ID: 20944179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of CYFRA21-1, Scc-Ag and telomerase activity in serum and pleural effusion of patients with squamous-cell lung cancer.
    Liu L; Liu B; Zhu LL; Zhang W; Li Y
    Bioanalysis; 2012 Oct; 4(19):2367-74. PubMed ID: 23088463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyfra 21-1 as a serum tumor marker for follow-up of patients with laryngeal and hypopharyngeal squamous cell carcinoma.
    Al-Shagahin H; Alkotyfan K; Müller HH; Sesterhenn AM; Werner JA
    Anticancer Res; 2009 Aug; 29(8):3421-5. PubMed ID: 19661367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical value of CEA and CYFRA21-1 as an assessment indicator of therapeutic efficacy in advanced non-small cell lung cancer patients].
    Li L; Song LH; Ding SC; Zhang XJ; Qiang L; Han CY; Yuan XT; Xu DD
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):850-4. PubMed ID: 21223692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis.
    Cui C; Sun X; Zhang J; Han D; Gu J
    J Cancer Res Ther; 2014 Nov; 10 Suppl():C131-4. PubMed ID: 25450270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive reactions for both Cyfra21-1 and CA125 indicate worst prognosis in non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Yamamoto N; Iida T
    Anticancer Res; 2003; 23(3C):2869-74. PubMed ID: 12926125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cyfra21-1 as a biomarker in patients with nonsmall cell lung cancer.
    Zhao H; Shi X; Liu J; Chen Z; Wang G
    J Cancer Res Ther; 2014 Nov; 10 Suppl():C215-7. PubMed ID: 25450285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer.
    Ando S; Suzuki M; Yamamoto N; Iida T; Kimura H
    Anticancer Res; 2004; 24(3b):1941-6. PubMed ID: 15274381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical value of serum cytokeratin 19 fragment and sialyl-Lewis x in non-small cell lung cancer.
    Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Kameyama M; Suehiro S
    Ann Thorac Surg; 2007 Jan; 83(1):216-21. PubMed ID: 17184666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
    Ma S; Shen L; Qian N; Chen K
    Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC).
    Cedrés S; Nuñez I; Longo M; Martinez P; Checa E; Torrejón D; Felip E
    Clin Lung Cancer; 2011 May; 12(3):172-9. PubMed ID: 21663860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.